Haemonetics Beats Q3 EPS Estimates with $1.31, Raises Full-Year Guidance
Haemonetics reported third-quarter fiscal 2026 earnings of $1.31 per share, surpassing the $1.27 Zacks consensus and rising from $1.19 a year earlier. The company issued updated full-year fiscal 2026 guidance and highlighted organic revenue growth metrics that exclude foreign exchange, divested blood products and CSL transition impacts.
1. Haemonetics Posts Q3 EPS Above Expectations
Haemonetics reported third quarter fiscal 2026 earnings of $1.31 per share, surpassing the consensus estimate of $1.27 and representing an increase from $1.19 per share in the year-ago period. The company released its Q3 and year-to-date results alongside an updated full-year guidance, with detailed disclosures provided in its Form 10-Q and supplemental earnings presentation. Management highlighted that reported and organic revenue growth rates exclude the impact of foreign exchange fluctuations, the divestiture of the whole blood product line and the strategic exit from certain liquid solution products. Investor materials are available on Haemonetics’ website and in this morning’s press release.